Evidence map›Paper›PMID 40670884›Full record

ArticleInfectious diseases and therapy2025

Impact of Revised Vaccination Recommendations for Mature Infants on Premature Infants' Vaccination Compliance in Germany.

Felicitas Kühne, Christof von Eiff, Julia Schiffner-Rohe, Lina Döring, Kathrin Gerchow, Karolin Seidel, Maren Laurenz

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Felicitas KühnePfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany. Felicitas.Kuehne@pfizer.com.ORCID http://orcid.org/0000-0001-9762-3842
Christof von EiffPfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany.
Julia Schiffner-RohePfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany.
Lina DöringPfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany.
Kathrin GerchowXcenda GmbH, part of Cencora, Lange Laube 31, 30159, Hannover, Germany.ORCID http://orcid.org/0000-0003-2769-0075
Karolin SeidelXcenda GmbH, part of Cencora, Lange Laube 31, 30159, Hannover, Germany.ORCID http://orcid.org/0000-0002-2682-5620
Maren LaurenzPfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe German Standing Committee on Vaccination (STIKO) changed the vaccination schedule for mature infants from a 3 + 1 to a 2 + 1 schedule for pneumococcal conjugate vaccines (PCV) in August 2015 and for hexavalent vaccines (HEXA) in August 2020. A 3 + 1 schedule is still recommended for premature infants for both vaccinations. This study analyzed the impact of the changed recommendations of PCV and HEXA vaccination on the vaccination compliance and adherence of premature infants.

methodsA retrospective claims data analysis was conducted using the InGef Research Database. The study population included all premature and mature infants born in 2013, 2016, 2018, and 2020 with an individual follow-up of 24 months. Premature infants were identified by ICD-10-GM codes P07.2 and P07.3. Documented records of vaccinations were assessed in the outpatient setting. Full vaccination rates of PCV and HEXA vaccination according to STIKO recommendations, valid in the respective observational year and maturity of birth, were analyzed.

resultsAfter the change in STIKO recommendations in 2020, the full HEXA vaccination rate for premature infants decreased significantly to 57.8% (2018, 71.0%), while it increased to 81.3% (2018, 73.8%) for mature infants. A similar pattern was observed during the transition from a 3 + 1 to a 2 + 1 PCV vaccination schedule among mature infants comparing birth cohorts 2013 (premature 65.4% vs mature 68.3%) and 2016 (premature 40.8% vs mature 75.6%).

conclusionDespite the continued recommendation for a 3 + 1 PCV and HEXA vaccination schedule in premature infants, a significant decrease of completed immunization was observed for both vaccines following the adjusted recommendations for mature infants. These findings underscore the need for enhanced efforts to promote adherence to STIKO guidelines to safeguard this vulnerable population of premature infants.

Indexed as

AdherenceChanges of STIKO recommendationClaims data analysisComplianceHexavalent vaccinationMature infantsPneumococcal conjugate vaccinationPremature infantsTimelinessVaccination rate

Identifiers

PMID40670884
PMCPMC12339820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.